Wednesday, August 28, 2013
• Lipidor AB, of Stockholm, a Karolinska Development portfolio firm, reported results from a Phase I/IIa study of AKVANO/calcipotriol spray formulation for the treatment of psoriasis vulgaris, which showed that the water-free spray had clear and significant antipsoriatic effects vs. placebo, comparable to a marketed formulation of calcipotriol, meeting the primary objective of the study.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.